FDA Approves KLYGEFA for Generalized Myasthenia Gravis
The FDA has cleared KLYGEFA (gefurulimab-gaks), the first dual-binding nanobody C5 inhibitor, as a treatment option for generalized myasthenia gravis (gMG). This approval represents a major win for the gMG community, offering a new path toward better symptom control and quality of life.
- 3 sources report it: manilatimes.net, finance.yahoo.com, ajmc.com.
- The source published it on Nov 16, 2026 at 3:35 AM.
Nothing open. Every check passed.
The FDA has greenlit KLYGEFA (gefurulimab-gaks), a first-of-its-kind dual-binding nanobody C5 inhibitor, marking a massive victory for the gMG community.
KLYGEFA is a new therapy from Alexion, AstraZeneca Rare Disease that targets the immune system’s key pathways involved in attacking the neuromuscular junction.
Data from the Phase III PREVAIL clinical trial showed patients saw improvement in their Myasthenia Gravis Activities of Daily Living (MG-ADL) scores starting as early as week one.
This progress was sustained through week 26 in the trial, which compared the treatment against a placebo.
The therapy arrives with a convenience feature: it is administered using a once-weekly, subcutaneous, self-administered autoinjector.
Angela Lek, PhD, Chief Research Officer at the Muscular Dystrophy Association, applauded the approval as meaningful progress for people living with gMG. She added that this innovation brings the community closer to personalized and effective treatments for long-term disease management.
TopicsKLYGEFA · gefurulimab-gaks · Alexion · AstraZeneca Rare Disease · Muscular Dystrophy Association · FDA · UCI Health
Written by AI from verified reporting.

